



BRITISH COLUMBIA
CENTRE *for* EXCELLENCE
in HIV/AIDS

B.C. HIV/AIDS Drug Treatment Program

Monthly Report

January 2020





© 2020 BC Centre for Excellence in HIV/AIDS

DISCLAIMER: This document is published by the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) as an overview of the activities of the BC-CfE's Drug Treatment Program. All information is generated from a live database maintained by the BC-CfE that houses data for clinical and virological outcome studies of patients receiving antiretroviral therapy.

This database is updated on a regular basis. Figures and tables provided in this Monthly Report represent the best estimates available at the time this document was generated.

Please be advised that information provided in this document is provided in good faith and is derived from sources believed to be accurate and up-to-date at the report's date of publication. The BC Centre for Excellence in HIV/AIDS nevertheless reserves the right to update this information at any time.

Information provided here at this time, is being provided freely, and no kind of agreement or contract is created between you and the authors. The authors cannot be responsible for any violations should you reproduce or republish the information contained herein.

Please note that the figures and graphs in this document are best viewed in colour.

**BC Centre for Excellence in HIV/AIDS
Drug Treatment Program**

St. Paul's Hospital
608 - 1081 Burrard Street
Vancouver, BC
V6Z 1Y6

Tel: 604.806.8515
Fax: 604.806.9044

Physician Drug Hotline: 1.800.665.7677
St. Paul's Hospital Pharmacy Hotline: 1.888.511.6222
Website: www.cfenet.ubc.ca
Email: info@cfenet.ubc.ca

Funding for the BC Centre for Excellence in HIV/AIDS is provided through Pharmacare and the Provincial Health Services Authority (PHSA)





EXECUTIVE SUMMARY

A key component of the BC Centre for Excellence in HIV/AIDS' (BC-CfE) mandate is to monitor the impact of HIV/AIDS in British Columbia. The BC-CfE provides essential information to local health authorities, treating physicians, and the community at large on an ongoing basis. The HIV/AIDS Drug Treatment Program (DTP) Update is one example of the BC-CfE's commitment to HIV-infected persons throughout the Province of British Columbia.

The DTP distributes anti-HIV drugs at no cost to eligible British Columbians. The DTP Update provides an important overview of available anti-HIV drugs, common drug combinations and distribution of active DTP participants throughout the province.

DTP participants are typically followed at three-monthly intervals at which time routine blood sampling is performed. Information from all recipients is entered into a database, providing data for clinical and virological outcome studies of patients receiving antiretroviral therapy. These studies form the basis of ongoing revisions to the BC-CfE's treatment guidelines.





TABLE OF CONTENTS

1. List of Figures

- 1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants
- 1.5 BC-CfE Enrolment: New Antiretroviral Participants
- 1.6 Percent Distribution of Active Participants by CD4 Count
- 1.7 Percent Distribution of Inactive Participants by CD4 Count
- 1.8 Active and Inactive Participants
- 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by Ingredient
- 1.12 Distribution of Participants on Protease Inhibitor by Ingredient
- 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by Ingredient
- 1.14 Distribution of Participants on Non-Nucleosides by Ingredient
- 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by Ingredient
- 1.16 Distribution of Participants on Entry/Integrase Inhibitors by Ingredient
- 1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by Ingredient
- 1.18 Baseline CD4 for Antiretroviral First Starts
- 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
- 1.20 Cumulative Resistance Testing Results by Resistance Category
- 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category

2. List of Tables

- 2.1 Duration of ARV treatment in the Province of BC, 1987-2012 (for HIV+ persons currently on treatment)
- 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program
- 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program
- 2.4 BC-CfE Enrolment
- 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 2.6 Number of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 2.7 Number of Participants on Protease Inhibitor by Ingredient
- 2.8 Number of Participants on Non-Nucleosides by Ingredient
- 2.9 Number of Participants on Entry/Integrase Inhibitors by Ingredient
- 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 2.11 Baseline CD4 for Antiretroviral First Starts
- 2.12 DTP Participants with PVL Measurement within previous five years, and never on ART





Table of Contents, cont'd...

3. Health Authority Maps

- 3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
- 3.2 Interior Health Authority & Kelowna
- 3.3 Fraser Health Authority & Surrey
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority & Victoria
- 3.6 Northern Health Authority & Prince George

4. Health Authority Tables

INTERIOR HEALTH

- 4.1 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries

FRASER HEALTH

- 4.4 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries

VANCOUVER COASTAL

- 4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries

VANCOUVER ISLAND

- 4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries

NORTHERN HEALTH

- 4.13 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries

ABORIGINAL

- 4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

5. Appendix

- 5.1 Drug Names and Definitions






1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority

January 2020

N = 7369



Health Authority	Male	Female	All
FRASER	1443	433	1876
INTERIOR	412	96	508
NORTHERN	133	88	221
VANCOUVER COASTAL	3339	451	3790
VANCOUVER ISLAND	780	160	940
	6107	1228	7335
		Unknown/not stated:	34
		Total:	7369

Definitions:


On antiretroviral therapy defined as being on treatment in the current month

Unknown/not stated defined as being on treatment in the current month, and city of residence unknown






1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (January 2015 - January 2020)






1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (January 2015 - January 2020)






1.4 BC-CfE Enrollment: Net Number of New Antiretroviral Participants (January 2015 - January 2020)






1.5 BC-CfE Enrollment: New Antiretroviral Participants (January 2015 - January 2020)






1.6 Percent Distribution of Active Participants by CD4 Count (January 2015 - January 2020)






1.7 Percent Distribution of Inactive Participants by CD4 Count
(January 2015 - January 2020)





1.8 Active and Inactive Participants
(January 2015 - January 2020)






1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs (January 2015 - January 2020)






1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (January 2015 - January 2020)






1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by INGREDIENT

(January 2015 - January 2020)






1.12 Distribution of Participants on Protease Inhibitor by INGREDIENT (January 2015 - January 2020)






1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by INGREDIENT

(January 2015 - January 2020)






1.14 Distribution of Participants on Non-Nucleosides by INGREDIENT (January 2015 - January 2020)






1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by INGREDIENT

(January 2015 - January 2020)






1.16 Distribution of Participants on Entry/Integrase Inhibitors by INGREDIENT (January 2015 - January 2020)






1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by INGREDIENT

(January 2015 - January 2020)






1.18 Baseline CD4 for Antiretroviral First Starts (January 2015 - January 2020)






**1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
(January 2015 - January 2020)**






1.20 Cumulative Resistance Testing Results by Resistance Category (January 2015 - January 2020)





1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category (January 2015 - January 2020)





**2.1 Duration of ARV treatment in the Province of BC, 1987-2020
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Median	Current PVL (n)	Median	Current ARV Median
1987	27	5	0	5	2	590	5	<40	3
1988	29	6	0	6	4	320	6	<40	3
1989	27	53	1	54	40	510	52	<40	3
1990	26	54	1	55	33	490	53	<40	3
1991	26	36	3	39	22	505	38	<40	3
1992	25	61	5	66	44	610	64	<40	3
1993	24	132	15	147	124	560	145	<40	3
1994	23	79	13	92	69	530	90	<40	3
1995	23	130	22	152	118	545	150	<40	3
1996	21	340	54	394	287	560	369	<40	3
1997	19	275	34	309	234	605	281	<40	3
1998	18	193	43	236	181	570	226	<40	3
1999	18	158	39	197	144	565	188	<40	3
2000	18	121	34	155	120	600	148	<40	3
2001	18	121	30	151	112	590	141	<40	3
2002	17	121	24	145	107	610	137	<40	3
2003	16	151	30	181	128	590	172	<40	3
2004	15	160	38	198	155	560	189	<40	3
2005	14	183	45	228	178	625	217	<40	3
2006	13	184	40	224	173	560	214	<40	3
2007	12	252	48	300	238	615	282	<40	3
2008	11	277	64	341	270	630	323	<40	3
2009	10	305	67	372	274	665	343	<40	3
2010	9	274	73	347	270	650	322	<40	3
2011	8	330	69	399	306	680	373	<40	3
2012	7	260	64	324	251	690	302	<40	3
2013	6	268	65	333	243	650	299	<40	3
2014	5	290	53	343	243	700	307	<40	3
2015	5	292	48	340	261	680	321	<40	3
2016	3	280	57	337	241	660	306	<40	3
2017	3	235	35	270	215	670	253	<40	3
2018	2	208	56	264	206	650	252	<40	3

Definitions:

On treatment defined as being on ARV therapy in the specified month and not reported deceased

Duration defined as cumulative years on ARV therapy, excluding periods of treatment interruption

Current CD4 and PVL tests defined as tests done in the last 6 months (most recent)

Current ARV defined as number of ARV drugs in the current regimen





**2.1 Duration of ARV treatment in the Province of BC, 1987-2020
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Median	Current PVL (n)	Median	Current ARV Median
2019	1	261	54	315	273	630	302	<40	3
2020	0	22	3	25	20	495	24	38700	3
Total:		6117	1227	7344					

Definitions:

On treatment defined as being on ARV therapy in the specified month and not reported deceased

Duration defined as cumulative years on ARV therapy, excluding periods of treatment interruption

Current CD4 and PVL tests defined as tests done in the last 6 months (most recent)

Current ARV defined as number of ARV drugs in the current regimen





2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program

MON-YYYY	# of patients	Median # of therapy days	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2019	7398	792	2456	<40	2145	610
FEB-2019	7379	799	1854	<40	1583	620
MAR-2019	7415	790	2085	<40	1752	610
APR-2019	7371	793	2143	<40	1748	610
MAY-2019	7431	792	2127	<40	1765	620
JUN-2019	7380	803	1928	<40	1594	616
JUL-2019	7391	806	2112	<40	1694	620
AUG-2019	7378	810	2108	<40	1620	607
SEP-2019	7356	806	2013	<40	1560	600
OCT-2019	7414	785	2141	<40	1730	620
NOV-2019	7357	781	2028	<40	1543	630
DEC-2019	7355	777	1701	<40	1212	615
JAN-2020	7369	778	2227	<40	1577	620

Definitions:

Active patient defined as being on ARV treatment in the specified month

Therapy days defined as number of consecutive days on ARV treatment (most recent uninterrupted period)

PVL and CD4 tests defined as tests done in the specified month





2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program

MON-YYYY	# of patients	Median # days of off therapy	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2019	1458	3450	73	73	65	350
FEB-2019	1488	3376	75	108	66	590
MAR-2019	1455	3511	74	636	61	400
APR-2019	1493	3414	80	<50	70	490
MAY-2019	1440	3662	78	87	69	450
JUN-2019	1495	3456	77	<40	69	510
JUL-2019	1482	3532	70	<40	57	530
AUG-2019	1506	3465	79	65	66	515
SEP-2019	1535	3348	94	<40	75	580
OCT-2019	1472	3655	80	120	67	470
NOV-2019	1496	3599	67	<40	54	560
DEC-2019	1484	3674	57	<40	47	480
JAN-2020	1465	3765	72	354	45	440

Definitions:

Inactive patient defined as not deceased, not being on ARV treatment in the specified month (but previously treated with ARVs)

Days off therapy defined as number of days elapsed since last ARV treatment

PVL and CD4 tests defined as tests done in the specified month





2.4 BC-CfE Enrollment

MON-YYYY	Currently on ARV Therapy	Currently off ARV Therapy	Deceased	First Starts	Experienced Starts	New Inactive	Net Change	Cumulative Patients
JAN-2019	7365	1458	14	20	191	159	35	13564
FEB-2019	7351	1488	7	16	160	180	-14	13593
MAR-2019	7374	1455	15	13	187	149	23	13613
APR-2019	7329	1493	10	15	152	181	-45	13641
MAY-2019	7393	1440	11	22	197	138	64	13684
JUN-2019	7340	1495	14	13	137	185	-53	13705
JUL-2019	7355	1482	13	13	181	163	15	13728
AUG-2019	7346	1506	12	18	167	176	-9	13764
SEP-2019	7321	1535	14	16	181	203	-25	13792
OCT-2019	7340	1472	3	13	222	145	19	13821
NOV-2019	7330	1496	9	17	158	167	-10	13854
DEC-2019	7327	1484	8	13	163	158	-3	13882
JAN-2020	7344	1465	8	13	181	160	17	13907

Definitions:

Currently on ARV Therapy defined as being on ARV treatment in the specified month, and not deceased/moved out of BC

Currently off ARV Therapy defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARVs in the past

Deceased defined as deceased in the specified month, and being on ARV treatment in the previous month

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Experienced Starts defined as starting ARV treatment in the specified month, but previously being treated with ARVs

New Inactive defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARV treatment in the previous month

Net Change is defined as difference between ARV starts (First and Experienced) and ARV stops (Deceased/Moved out of BC and New Inactive)





2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs

MON-YYYY	Less than 3 Drugs	3 Drugs	4 Drugs	5 or more Drugs	All ARV	Less than 3 Drugs%	3 Drugs%	4 Drugs%	5 or more Drugs%	Total%
JAN-2019	55	6804	486	53	7398	0.74%	91.97%	6.57%	0.72%	100.00%
FEB-2019	53	6785	492	49	7379	0.72%	91.95%	6.67%	0.66%	100.00%
MAR-2019	60	6815	490	50	7415	0.81%	91.91%	6.61%	0.67%	100.00%
APR-2019	56	6777	490	48	7371	0.76%	91.94%	6.65%	0.65%	100.00%
MAY-2019	55	6839	492	45	7431	0.74%	92.03%	6.62%	0.61%	100.00%
JUN-2019	57	6794	481	48	7380	0.77%	92.06%	6.52%	0.65%	100.00%
JUL-2019	60	6792	491	48	7391	0.81%	91.90%	6.64%	0.65%	100.00%
AUG-2019	59	6785	484	50	7378	0.80%	91.96%	6.56%	0.68%	100.00%
SEP-2019	57	6761	486	52	7356	0.77%	91.91%	6.61%	0.71%	100.00%
OCT-2019	60	6813	488	53	7414	0.81%	91.89%	6.58%	0.71%	100.00%
NOV-2019	59	6762	486	50	7357	0.80%	91.91%	6.61%	0.68%	100.00%
DEC-2019	60	6769	478	48	7355	0.82%	92.03%	6.50%	0.65%	100.00%
JAN-2020	60	6768	484	57	7369	0.81%	91.84%	6.57%	0.77%	100.00%

Definitions:

Number of Drugs is calculated as number of individual drugs in ARV Therapy (excluding low dose ritonavir used for boosting a protease inhibitor)





2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT

	lamivudine		abacavir		zidovudine		stavudine		didanosine		tenofovir <TAF>		tenofovir <TDF>	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2019	8 23%	3471 48%	7 20%	3258 45%	1 3%	45 1%	0 0%	4 0%	0 0%	1 0%	1 3%	519 7%	26 74%	3359 47%
FEB-2019	13 45%	3464 48%	12 41%	3263 45%	0 0%	44 1%	0 0%	1 0%	0 0%	1 0%	3 10%	542 8%	13 45%	3309 46%
MAR-2019	6 30%	3475 48%	6 30%	3278 45%	0 0%	43 1%	0 0%	2 0%	0 0%	0 0%	2 10%	559 8%	12 60%	3309 46%
APR-2019	12 43%	3476 48%	12 43%	3284 46%	0 0%	43 1%	0 0%	2 0%	0 0%	0 0%	2 7%	586 8%	14 50%	3252 45%
MAY-2019	14 33%	3507 48%	14 33%	3315 46%	0 0%	43 1%	0 0%	2 0%	0 0%	1 0%	4 10%	593 8%	24 57%	3265 45%
JUN-2019	3 14%	3489 49%	3 14%	3301 46%	0 0%	43 1%	0 0%	2 0%	0 0%	1 0%	2 10%	610 8%	16 76%	3208 45%
JUL-2019	8 36%	3512 49%	8 36%	3331 46%	0 0%	39 1%	0 0%	2 0%	0 0%	1 0%	1 5%	626 9%	13 59%	3191 44%
AUG-2019	14 39%	3516 49%	12 33%	3341 47%	2 6%	41 1%	0 0%	1 0%	0 0%	1 0%	2 6%	632 9%	20 56%	3154 44%
SEP-2019	6 21%	3499 49%	6 21%	3323 46%	0 0%	39 1%	0 0%	1 0%	0 0%	1 0%	5 18%	656 9%	17 61%	3131 44%
OCT-2019	4 14%	3521 49%	2 7%	3339 46%	0 0%	38 1%	0 0%	1 0%	0 0%	1 0%	1 4%	671 9%	23 82%	3155 44%
NOV-2019	8 24%	3463 48%	7 21%	3286 46%	1 3%	37 1%	0 0%	1 0%	0 0%	1 0%	6 18%	730 10%	19 58%	3123 44%
DEC-2019	1 4%	3443 48%	1 4%	3265 46%	0 0%	37 1%	0 0%	1 0%	0 0%	1 0%	14 50%	857 12%	13 46%	3059 43%
JAN-2020	3 12%	3410 47%	3 12%	3234 45%	0 0%	34 0%	0 0%	1 0%	0 0%	0 0%	9 36%	1028 14%	13 52%	2965 41%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





Monthly Report

2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (continued)

	emtricitabine			
	Initial		All	
JAN-2019	27	77%	3698	51%
FEB-2019	16	55%	3678	51%
MAR-2019	14	70%	3705	51%
APR-2019	16	57%	3668	51%
MAY-2019	28	67%	3694	51%
JUN-2019	18	86%	3655	51%
JUL-2019	14	64%	3665	51%
AUG-2019	22	61%	3638	51%
SEP-2019	22	79%	3635	51%
OCT-2019	24	86%	3679	51%
NOV-2019	25	76%	3681	51%
DEC-2019	27	96%	3720	52%
JAN-2020	22	88%	3768	52%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.7 Number of Participants on Protease Inhibitor by INGREDIENT

	fosamprenavir		atazanavir		darunavir		lopinavir		nelfinavir		ritonavir		saquinavir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2019	0 0%	6 0%	1 8%	1098 40%	11 92%	1478 54%	0 0%	140 5%	0 0%	0 0%	0 0%	1 0%	0 0%	9 0%
FEB-2019	0 0%	5 0%	2 18%	1071 40%	9 82%	1475 55%	0 0%	138 5%	0 0%	0 0%	0 0%	1 0%	0 0%	9 0%
MAR-2019	0 0%	5 0%	2 40%	1053 39%	3 60%	1487 55%	0 0%	132 5%	0 0%	1 0%	0 0%	1 0%	0 0%	7 0%
APR-2019	0 0%	5 0%	1 10%	1028 39%	7 70%	1478 56%	2 20%	132 5%	0 0%	2 0%	0 0%	1 0%	0 0%	7 0%
MAY-2019	0 0%	5 0%	1 8%	1034 39%	11 92%	1480 56%	0 0%	130 5%	0 0%	2 0%	0 0%	1 0%	0 0%	6 0%
JUN-2019	0 0%	5 0%	0 0%	1003 39%	9 100%	1467 57%	0 0%	120 5%	0 0%	1 0%	0 0%	1 0%	0 0%	6 0%
JUL-2019	0 0%	5 0%	0 0%	983 38%	6 100%	1487 58%	0 0%	113 4%	0 0%	1 0%	0 0%	1 0%	0 0%	6 0%
AUG-2019	0 0%	5 0%	0 0%	970 38%	11 92%	1462 57%	1 8%	112 4%	0 0%	1 0%	0 0%	1 0%	0 0%	5 0%
SEP-2019	0 0%	4 0%	1 8%	955 37%	12 92%	1484 58%	0 0%	110 4%	0 0%	1 0%	0 0%	1 0%	0 0%	6 0%
OCT-2019	0 0%	4 0%	1 7%	959 37%	13 93%	1495 58%	0 0%	109 4%	0 0%	1 0%	0 0%	1 0%	0 0%	6 0%
NOV-2019	0 0%	4 0%	0 0%	941 37%	3 100%	1473 58%	0 0%	102 4%	0 0%	1 0%	0 0%	1 0%	0 0%	6 0%
DEC-2019	0 0%	4 0%	0 0%	925 37%	7 100%	1467 59%	0 0%	100 4%	0 0%	1 0%	0 0%	1 0%	0 0%	6 0%
JAN-2020	0 0%	2 0%	0 0%	911 37%	7 88%	1469 59%	1 13%	97 4%	0 0%	0 0%	0 0%	1 0%	0 0%	6 0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





Monthly Report

2.7 Number of Participants on Protease Inhibitor by INGREDIENT (continued)

	tipranavir			
	Initial		All	
JAN-2019	0	0%	1	0%
FEB-2019	0	0%	1	0%
MAR-2019	0	0%	1	0%
APR-2019	0	0%	1	0%
MAY-2019	0	0%	1	0%
JUN-2019	0	0%	1	0%
JUL-2019	0	0%	1	0%
AUG-2019	0	0%	1	0%
SEP-2019	0	0%	1	0%
OCT-2019	0	0%	1	0%
NOV-2019	0	0%	1	0%
DEC-2019	0	0%	1	0%
JAN-2020	0	0%	1	0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





2.8 Number of Participants on Non-Nucleosides by INGREDIENT

	doravirine		efavirenz		etravirine		nevirapine		rilpivirine	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2019	0 0%	0 0%	4 80%	669 35%	0 0%	221 12%	1 20%	695 37%	0 0%	318 17%
FEB-2019	0 0%	0 0%	2 67%	668 35%	1 33%	226 12%	0 0%	683 36%	0 0%	313 17%
MAR-2019	0 0%	0 0%	3 75%	660 35%	0 0%	224 12%	1 25%	681 36%	0 0%	322 17%
APR-2019	0 0%	0 0%	4 100%	646 35%	0 0%	223 12%	0 0%	678 36%	0 0%	320 17%
MAY-2019	0 0%	0 0%	6 100%	648 35%	0 0%	219 12%	0 0%	672 36%	0 0%	322 17%
JUN-2019	0 0%	0 0%	3 75%	636 35%	0 0%	211 12%	0 0%	664 36%	1 25%	320 18%
JUL-2019	0 0%	1 0%	2 100%	636 35%	0 0%	211 12%	0 0%	657 36%	0 0%	323 18%
AUG-2019	0 0%	1 0%	2 100%	626 35%	0 0%	207 11%	0 0%	647 36%	0 0%	327 18%
SEP-2019	0 0%	1 0%	4 80%	611 35%	0 0%	209 12%	0 0%	622 35%	1 20%	325 18%
OCT-2019	0 0%	1 0%	6 60%	614 35%	1 10%	211 12%	2 20%	596 34%	1 10%	330 19%
NOV-2019	0 0%	1 0%	5 71%	615 37%	0 0%	209 12%	1 14%	525 31%	1 14%	326 19%
DEC-2019	0 0%	1 0%	3 100%	608 37%	0 0%	203 12%	0 0%	513 31%	0 0%	325 20%
JAN-2020	0 0%	1 0%	2 100%	588 36%	0 0%	202 13%	0 0%	502 31%	0 0%	325 20%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Doravirine not currently available on BC-CfE Formulary





2.9 Number of Participants on Entry/Integrase Inhibitors by INGREDIENT

	bictegravir		dolutegravir		elvitegravir		maraviroc		raltegravir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2019	0 0%	16 0%	15 75%	2430 63%	4 20%	730 19%	0 0%	39 1%	1 5%	651 17%
FEB-2019	0 0%	27 1%	16 73%	2436 63%	5 23%	727 19%	0 0%	40 1%	1 5%	653 17%
MAR-2019	0 0%	27 1%	8 62%	2483 64%	5 38%	747 19%	0 0%	38 1%	0 0%	647 17%
APR-2019	0 0%	27 1%	8 57%	2499 64%	3 21%	739 19%	0 0%	36 1%	3 21%	637 16%
MAY-2019	0 0%	27 1%	19 68%	2563 64%	6 21%	748 19%	0 0%	37 1%	3 11%	636 16%
JUN-2019	0 0%	27 1%	10 77%	2566 65%	3 23%	746 19%	0 0%	37 1%	0 0%	625 16%
JUL-2019	0 0%	27 1%	13 81%	2611 65%	3 19%	758 19%	0 0%	38 1%	0 0%	628 16%
AUG-2019	0 0%	27 1%	24 86%	2650 65%	1 4%	756 19%	0 0%	36 1%	3 11%	627 15%
SEP-2019	0 0%	28 1%	8 50%	2656 65%	6 38%	758 19%	0 0%	37 1%	2 13%	630 15%
OCT-2019	0 0%	28 1%	13 87%	2728 66%	1 7%	759 18%	0 0%	34 1%	1 7%	631 15%
NOV-2019	3 13%	88 2%	16 70%	2748 65%	4 17%	772 18%	0 0%	33 1%	0 0%	623 15%
DEC-2019	13 65%	231 5%	6 30%	2726 64%	1 5%	746 18%	0 0%	33 1%	0 0%	606 14%
JAN-2020	9 47%	423 10%	8 42%	2695 62%	0 0%	707 16%	0 0%	32 1%	2 11%	595 14%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class

MON-YYYY	Boosted PI + 2 NRTIs		NNRTI + 2 NRTIs		Integrase + 2 NRTIs		Un-boosted PI + 2 NRTIs		MDRT		Other	
	n	%	n	%	n	%	n	%	n	%	n	%
JAN-2019	1833	24.78	1481	20.02	3062	41.39	100	1.35	53	0.72	869	11.75
FEB-2019	1805	24.46	1479	20.04	3078	41.71	99	1.34	49	0.66	869	11.78
MAR-2019	1794	24.19	1473	19.87	3129	42.20	98	1.32	50	0.67	871	11.75
APR-2019	1761	23.89	1461	19.82	3144	42.65	100	1.36	48	0.65	857	11.63
MAY-2019	1774	23.87	1450	19.51	3207	43.16	97	1.31	45	0.61	858	11.55
JUN-2019	1744	23.63	1441	19.53	3209	43.48	95	1.29	48	0.65	843	11.42
JUL-2019	1718	23.24	1430	19.35	3246	43.92	92	1.24	48	0.65	857	11.60
AUG-2019	1689	22.89	1405	19.04	3298	44.70	94	1.27	50	0.68	842	11.41
SEP-2019	1699	23.10	1365	18.56	3307	44.96	93	1.26	52	0.71	840	11.42
OCT-2019	1707	23.02	1345	18.14	3369	45.44	93	1.25	53	0.71	847	11.42
NOV-2019	1669	22.69	1274	17.32	3434	46.68	91	1.24	50	0.68	839	11.40
DEC-2019	1644	22.35	1250	17.00	3494	47.51	92	1.25	48	0.65	827	11.24
JAN-2020	1621	22.00	1207	16.38	3571	48.46	87	1.18	57	0.77	826	11.21

Definitions:

n is number of participants on the specified regimen class in the specified month

% is ratio of n and total number of participants on ART in the specified month





2.11 Baseline CD4 for Antiretroviral First Starts

MON-YYYY	# of First Starts	# of Pts with CD4 < 100	# of Pts with CD4: 100-199	# of Pts with CD4: 200-349	# of Pts with CD4: 350-500	# of Pts with CD4 > 500	Median CD4
JAN-2019	20	3	3	2	4	6	390
FEB-2019	16	1	0	6	4	4	400
MAR-2019	13	1	2	1	5	4	450
APR-2019	15	3	3	1	2	4	340
MAY-2019	22	1	0	6	8	4	440
JUN-2019	13	2	1	1	2	5	430
JUL-2019	13	1	1	1	3	7	530
AUG-2019	18	0	1	6	4	6	390
SEP-2019	16	0	0	2	4	8	535
OCT-2019	13	1	1	3	4	3	415
NOV-2019	17	4	1	1	1	10	520
DEC-2019	13	0	2	5	2	4	300
JAN-2020	13	0	2	1	4	5	495

Definitions:

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Baseline CD4 is defined as most recent CD4 test before ARV start





2.12 DTP Participants with PVL Measurement within previous five years, and never on ART

MON-YYYY	# of Participants with PVL test	# of Participants with PVL test, and never on ART
JAN-2019	12253	3831
FEB-2019	12261	3830
MAR-2019	12291	3860
APR-2019	12318	3884
MAY-2019	12334	3885
JUN-2019	12334	3890
JUL-2019	12351	3905
AUG-2019	12383	3922
SEP-2019	12402	3939
OCT-2019	12436	3963
NOV-2019	12458	3972
DEC-2019	12482	3986
JAN-2020	12547	4039

Definitions:

Patients with PVL test are defined as having at least one PVL test within previous five years, and not reported deceased/moved
Never on ART are subset of patients with PVL test, and not being treated with ARVs on or before specified month







3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
January 2020

N = 7369

BY HEALTH SERVICES DELIVERY AREA



BY HEALTH AUTHORITY







3.2 Distribution of HIV/AIDS Drug Treatment Program Active Participants

January 2020

INTERIOR HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



KELOWNA BY POSTAL CODE







3.3 Distribution of HIV/AIDS Drug Treatment Program Active Participants

January 2020

FRASER HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



SURREY BY POSTAL CODE







3.4 Distribution of HIV/AIDS Drug Treatment Program Active Participants

January 2020

VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VANCOUVER BY POSTAL CODE







3.5 Distribution of HIV/AIDS Drug Treatment Program Active Participants

January 2020

VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VICTORIA BY POSTAL CODE







3.6 Distribution of HIV/AIDS Drug Treatment Program Active Participants

January 2020

NORTHERN HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



PRINCE GEORGE BY POSTAL CODE





4.1 Distribution of Participants in BC-CfE Registries by Age and Gender INTERIOR Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
EAST KOOTENAY	20-34	6	6	*
	35-49	9	10	*
	50+	28	40	*
	Total HSDA:	43	56	29
KOOTENAY BOUNDARY	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HSDA:	73	97	52	
OKANAGAN	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HSDA:	365	496	279	
THOMPSON/CARIBOO/ SHUSWAP	0-19	*	*	0
	20-34	*	*	14
	35-49	*	*	54
	50+	*	*	80
Total HSDA:	192	263	148	
Total HA:		673	912	508

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	5	5	*
	20-34	62	63	*
	35-49	176	197	*
	50+	430	647	*
Total HA:		673	912	508

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	540	731	412
Female	133	181	96

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	508	55	610	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration INTERIOR Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
EAST KOOTENAY	10 years or more	18	11
	5 years or more	12	6
	<5 years	13	12
	Total HSDA:	43	29
KOOTENAY BOUNDARY	10 years or more	45	31
	5 years or more	16	11
	<5 years	12	10
	Total HSDA:	73	52
OKANAGAN	10 years or more	225	161
	5 years or more	71	59
	<5 years	69	59
	Total HSDA:	365	279
THOMPSON/CARIBOO/ SHUSWAP	10 years or more	106	77
	5 years or more	44	39
	<5 years	42	32
	Total HSDA:	192	148
Total HA:		673	508

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	394	280
5 years or more	143	115
<5 years	136	113
Total HA:	673	508

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries INTERIOR Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
EAST KOOTENAY	45	64	15	25
KOOTENAY BOUNDARY	76	122	26	44
OKANAGAN	224	928	58	288
THOMPSON/CARIBOO/SHUSWAP	138	516	39	141
Total:	483	1630	138	498

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
EAST KOOTENAY	*
KOOTENAY BOUNDARY	*
OKANAGAN	*
THOMPSON/CARIBOO/SHUSWAP	*
Total:	91

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.4 Distribution of Participants in BC-CfE Registries by Age and Gender FRASER Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
FRASER EAST	0-19	7	7	6
	20-34	28	30	20
	35-49	103	113	78
	50+	238	313	185
	Total HSDA:		376	463
FRASER NORTH	0-19	7	7	*
	20-34	117	118	*
	35-49	341	369	*
	50+	563	889	*
	Total HSDA:		1028	1383
FRASER SOUTH	0-19	7	7	*
	20-34	114	116	*
	35-49	332	377	*
	50+	551	810	*
	Total HSDA:		1004	1310
Total HA:		2408	3156	1876

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	21	21	12
	20-34	259	264	179
	35-49	776	859	601
	50+	1352	2012	1084
Total HA:		2408	3156	1876

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	1829	2419	1443
Female	579	737	433

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	1876	52	630	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
FRASER Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
FRASER EAST	10 years or more	223	170
	5 years or more	73	58
	<5 years	80	61
	Total HSDA:	376	289
FRASER NORTH	10 years or more	577	413
	5 years or more	247	194
	<5 years	204	167
	Total HSDA:	1028	774
FRASER SOUTH	10 years or more	556	444
	5 years or more	229	175
	<5 years	219	194
	Total HSDA:	1004	813
Total HA:		2408	1876

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	1356	1027
	5 years or more	549	427
	<5 years	503	422
Total HA:		2408	1876

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries
FRASER Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
FRASER EAST	145	495	31	57
FRASER NORTH	257	1573	52	236
FRASER SOUTH	224	1482	51	466
Total:	626	3550	134	759

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
FRASER EAST	199
FRASER NORTH	640
FRASER SOUTH	504
Total:	1343

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
VANCOUVER COASTAL Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		345	493
RICHMOND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		173	222
VANCOUVER	0-19	26	26	6
	20-34	444	459	311
	35-49	1365	1538	977
	50+	2832	4842	2070
	Total HSDA:	4667	6865	3364
Total HA:		5185	7580	3790

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	30	30	8
	20-34	498	514	355
	35-49	1490	1675	1074
	50+	3167	5361	2353
Total HA:		5185	7580	3790

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Unknown	2	2	0
Male	4579	6656	3339
Female	604	922	451

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	3790	53	640	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER COASTAL Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	10 years or more	188	152
	5 years or more	87	76
	<5 years	70	64
	Total HSDA:	345	292
RICHMOND	10 years or more	101	74
	5 years or more	36	28
	<5 years	36	32
	Total HSDA:	173	134
VANCOUVER	10 years or more	2791	1927
	5 years or more	1123	815
	<5 years	753	622
	Total HSDA:	4667	3364
Total HA:		5185	3790

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	3080	2153
5 years or more	1246	919
<5 years	859	718
Total HA:	5185	3790

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries
VANCOUVER COASTAL Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH SHORE/COAST GARIBALDI	181	499	59	177
RICHMOND	44	288	12	93
VANCOUVER	641	10867	222	5275
Total:	866	11654	293	5545

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH SHORE/COAST GARIBALDI	7
RICHMOND	5
VANCOUVER	112
Total:	124

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
VANCOUVER ISLAND Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		329	464
NORTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		127	169
SOUTH VANCOUVER ISLAND	0-19	*	*	0
	20-34	*	*	54
	35-49	*	*	146
	50+	*	*	371
	Total HSDA:		743	1049
Total HA:		1199	1682	940

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HA:		1199	1682	940

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	990	1386	780
Female	209	296	160

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	940	54	570	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER ISLAND Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	10 years or more	181	148
	5 years or more	72	57
	<5 years	76	60
	Total HSDA:	329	265
NORTH VANCOUVER ISLAND	10 years or more	73	59
	5 years or more	34	27
	<5 years	20	18
	Total HSDA:	127	104
SOUTH VANCOUVER ISLAND	10 years or more	435	313
	5 years or more	160	136
	<5 years	148	122
	Total HSDA:	743	571
Total HA:		1199	940

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	689	520
5 years or more	266	220
<5 years	244	200
Total HA:	1199	940

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries
VANCOUVER ISLAND Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
CENTRAL VANCOUVER ISLAND	201	866	80	199
NORTH VANCOUVER ISLAND	150	268	52	80
SOUTH VANCOUVER ISLAND	217	1793	45	556
Total:	568	2927	177	835

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
CENTRAL VANCOUVER ISLAND	50
NORTH VANCOUVER ISLAND	39
SOUTH VANCOUVER ISLAND	111
Total:	200

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.13 Distribution of Participants in BC-CfE Registries by Age and Gender
NORTHERN Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH EAST	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		41	49
NORTH WEST	20-34	11	12	6
	35-49	17	33	14
	50+	41	64	33
	Total HSDA:	69	109	53
NORTHERN INTERIOR	0-19	5	5	*
	20-34	25	26	*
	35-49	71	90	*
	50+	91	152	*
	Total HSDA:	192	273	143
Total HA:		302	431	221

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	6	6	*
	20-34	39	41	*
	35-49	107	145	*
	50+	150	239	*
Total HA:		302	431	221

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	183	266	133
Female	119	165	88

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	221	50	560	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
NORTHERN Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH EAST	10 years or more	21	*
	5 years or more	14	*
	<5 years	6	*
	Total HSDA:	41	25
NORTH WEST	10 years or more	35	24
	5 years or more	21	18
	<5 years	13	11
	Total HSDA:	69	53
NORTHERN INTERIOR	10 years or more	77	55
	5 years or more	62	49
	<5 years	53	39
	Total HSDA:	192	143
Total HA:		302	221

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	133	90
	5 years or more	97	77
	<5 years	72	54
Total HA:		302	221

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries NORTHERN Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH EAST	42	63	7	8
NORTH WEST	80	163	15	31
NORTHERN INTERIOR	115	467	19	181
Total:	237	693	41	220

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH EAST	7
NORTH WEST	19
NORTHERN INTERIOR	14
Total:	40

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

HA	HSDA	Alive	Ever treated with ARVs	Currently treated with ARVs
INTERIOR	EAST KOOTENAY	6	10	5
	KOOTENAY BOUNDARY	6	9	6
	OKANAGAN	23	39	14
	THOMPSON/CARIBOO/SHUSWAP	26	47	21
	Total HA:	61	105	46
FRASER	FRASER EAST	39	49	29
	FRASER NORTH	53	89	44
	FRASER SOUTH	75	108	57
	Total HA:	167	246	130
VANCOUVER COASTAL	NORTH SHORE/COAST GARIBALDI	27	50	24
	RICHMOND	8	13	6
	VANCOUVER	484	858	387
	Total HA:	519	921	417
VANCOUVER ISLAND	CENTRAL VANCOUVER ISLAND	51	80	41
	NORTH VANCOUVER ISLAND	19	28	16
	SOUTH VANCOUVER ISLAND	38	81	32
	Total HA:	108	189	89
NORTHERN	NORTH EAST	11	13	9
	NORTH WEST	27	58	22
	NORTHERN INTERIOR	74	111	63
	Total HA:	112	182	94
Total:		967	1643	776

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	608	1048	488
Female	359	595	288

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total:	776	52	480	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





5.1 Drug Names and Definitions

Abacavir (Ziagen, ABC): a NUCLEOSIDE ANALOG from ViiV Healthcare.

Active: persons in the HIV/AIDS Drug Treatment program that are prescribed one or more drugs in this current month

Amphotericin B (Fungilin): a drug used for treatment of candidiasis and other fungal infections.

Amprenavir (Agenerase, APV): a PROTEASE INHIBITOR from ViiV Healthcare. No longer marketed in Canada.

Antiretroviral (ARV): a substance that stops or suppresses the activity of a retrovirus, such as HIV. NUCLEOSIDE ANALOGS and PROTEASE INHIBITORS are examples of antiretroviral drugs.

Atazanavir (Reyataz, ATV): a PROTEASE INHIBITOR from Bristol-Myers Squibb.

Atovaquone (Mepron): a medication used to treat pneumocystis carinii pneumonia and, in some cases, toxoplasmosis.

Atripla (ATP): the Bristol-Myers Squibb and Gilead trade name for a tablet containing EFAVIRENZ, TENOFOVIR DF and EMTRICITABINE.

Azithromycin (Zithromax): an antibiotic used for the prevention of mycobacterium avium complex (MAC) in people with advanced HIV infection.

Bictegravir: an INTEGRASE INHIBITOR from Gilead Sciences.

Boosted PI: a PI and a small (400 mg or less, total daily dose) additional dose or RITONAVIR. The addition of RITONAVIR inhibits metabolism of other PIs and improves their exposure. This may allow for decreased dosing frequency or pill burden and may improve adherence and antiretroviral activity.

CD4 Cell Count: the most commonly used marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. Normal CD4 cell counts are greater than 800 per cubic millimeter of blood.

Chemokine Receptor Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV entry by blocking the binding site of co-receptors, such as CCR5 or CXCR4.

Clarithromycin (Biaxin): an antibiotic used for the treatment of mycobacterium avium complex (MAC). It is also used for preventing MAC in those with advanced HIV infection.

Cobicistat: a pharmacokinetic enhancer (“booster”) given with other antiretrovirals to improve drug exposure. Cobicistat has no anti-HIV activity. It is currently available as a component of STRIBILD, GENVOYA and PREZCOBIX.

Combination Therapy: initial combination therapy for HIV contains at least three ANTIRETROVIRALS.

Combivir (CBV): the ViiV Healthcare trade name for a tablet containing both ZIDOVUDINE and LAMIVUDINE.

Complera (CPL): the Gilead trade name for a tablet containing EMTRICITABINE, RILPIVIRINE and TENOFOVIR DF.

Darunavir (Prezista, DRV): a PROTEASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Deceased: persons enrolled in the HIV/AIDS Drug Treatment program that died in this time period.





Monthly Report

Descovy (DSC): the Gilead trade name for a tablet containing EMTRICITABINE and TENOFOVIR AF.

Didanosine (Videx, DDI): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Dolutegravir (Tivicay, DTG): an INTEGRASE INHIBITOR from ViiV Healthcare.

Doravirine: a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Merck.

Efavirenz (Sustiva, Auro efavirenz, EFV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Bristol-Myers Squibb.

Elvitegravir (EGV): an INTEGRASE INHIBITOR from Gilead Sciences. It is currently available as a component of STRIBILD.

Emtricitabine (FTC): a NUCLEOSIDE ANALOG from Gilead Sciences. It is currently available as a component of TRUVADA and other combinations.

Enfuvirtide (Fuzeon, T20): a FUSION INHIBITOR from Hoffman-La Roche that targets the gp41 protein on the surface of HIV. It is administered as a subcutaneous injection.

Entry Inhibitor: a drug that inhibits the entry of HIV into cells. Entry inhibitors include FUSION INHIBITORS, CHEMOKINE RECEPTOR INHIBITORS, and attachment inhibitors.

Etravirine (Intelence, ETV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Ethambutol (Myambutol): an antibiotic used in COMBINATION THERAPY for treatment of mycobacterial infections such as tuberculosis and mycobacterium avium complex (MAC).

First started program: a person prescribed their first regimen ever in the HIV/AIDS drug treatment program.

Fosamprenavir (Telzir, fAPV): a PROTEASE INHIBITOR from ViiV Healthcare. Fosamprenavir is a PRODRUG of AMPRENAVIR.

Fusion Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV from fusing with and thereby infecting CD4 cells.

Genvoya (GNV): the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICSTAT, EMTRICITABINE and TENOFOVIR AF.

Granulocyte Colony Stimulating Factor (GCSF, Neupogen): a natural hormone that stimulates production of granulocytes, a type of white blood cell (leukocyte).

Health Authority: refers to the five (Interior, Fraser, Northern, Vancouver Coastal, Vancouver Island) health authorities created by the BC Ministry of Health.

Inactive: persons no longer dispensed drugs through the HIV/AIDS Drug Treatment program this current month.

Integrase Inhibitor: a drug that blocks integrase, a protein that HIV needs to enter cells and produce copies of itself, from working.

Kivexa (KIV): the ViiV Healthcare's trade name for a tablet containing both ABACAVIR and LAMIVUDINE.

Lamivudine (3TC): a NUCLEOSIDE ANALOG from ViiV Healthcare with activity against HIV and hepatitis B.

Lopinavir (Kaletra, LPV/r): a PROTEASE INHIBITOR from Abbott Laboratories. Kaletra is a combination of lopinavir and a low dose of RITONAVIR, a drug that improves blood levels of lopinavir.





Monthly Report

Maraviroc (Celsentri, MVC): a CHEMOKINE RECEPTOR INHIBITOR from ViiV Healthcare that inhibits HIV entry by blocking the binding site of the CCR5 co-receptor.

Median (MED) age: median age of participants in the HIV/AIDS Drug Treatment program in that time period.

MDRT: see MULTIPLE DRUG RESCUE THERAPY

Moved out of BC: a person in the HIV/AIDS Drug Treatment program that is no longer in the program, because they moved out of BC in this time period.

Moxifloxacin: a fluoroquinolone antibiotic that is used for treatment of mycobacterium avium complex which is resistant to clarithromycin.

Multiple Drug Rescue Therapy (MDRT or Mega-HAART): the use of five or more antiretrovirals to treat HIV, typically some or all of which have been used previously by the individual.

Nelfinavir (Viracept, NFV): a PROTEASE INHIBITOR from ViiV Healthcare.

Net change: the net increase or decrease in persons enrolled in the HIV/AIDS Drug Treatment Program from the previous time period.

Nevirapine (Viramune, NVP): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Boehringer Ingelheim.

NNRTI: see NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR.

NNRTI / no PI: a combination therapy regimen of four or fewer antiretroviral drugs, including an NNRTI, but no PIs.

Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI): a member of a class of compounds, including DELAVIRDINE, NEVIRAPINE, EFAVIRENZ and ETRAVIRINE that acts to directly combine with and block the action of HIV's reverse transcriptase enzyme.

NRTI: see NUCLEOSIDE ANALOG.

Nucleoside Analog (Nucleoside Analog Reverse Transcriptase Inhibitor, NRTI): a type of ANTIVIRAL drug whose structure constitutes a defective version of a natural nucleoside. Nucleoside analogs may take the place of the natural nucleosides, blocking the completion of a viral DNA chain during infection of a new cell by HIV. The HIV enzyme reverse transcriptase is more likely to incorporate nucleoside analogs into the DNA it is constructing than is the DNA polymerase that cells normally use for DNA construction.

Nucleotide Analog: ANTIVIRAL compounds that function exactly like NUCLEOSIDE ANALOGS but are pre-activated through the addition of a phosphate group during their synthesis. This phosphorylation is supposed to enhance the drug levels and activity achieved within cells.

Octreotide Acetate (Sandostatin): a drug used to treat chronic refractory diarrhea.

Odefsey (ODF): the Gilead trade name for a tablet containing RILPIVIRINE, EMTRICITABINE and TENOFOVIR AF.

One or more PI: a combination therapy regimen of four or fewer antiretroviral drugs, including one unboosted PI or 2 or more PIs with or without a small (400 mg or less, total daily dose) additional dose of RITONAVIR.

Other: an antiretroviral regimen in the HIV/AIDS Drug Treatment program other than NNRTI/no PI, boosted PI, 1 or more PIs or MDRT-based regimens (eg. Triple Nucleoside regimens).

Paromomycin (Humatin): an antibiotic used to treat infections caused by intestinal parasites, including AIDS-related cryptosporidiosis.





Monthly Report

Pentamidine: an antiprotozoal drug used in aerosol form as a preventative against pneumocystis carinii pneumonia (PCP).

PI: see PROTEASE INHIBITOR.

Prezcobix (PZC): the Janssen trade name for a tablet containing DARUNAVIR and COBICISTAT.

Prodrug: a compound that is converted within the body into the active form that has medical effects.

Protease Inhibitor: a drug that binds to and blocks HIV protease from working, thus preventing the production of new functional viral particles.

Raltegravir (RGV, Isentress): an INTEGRASE INHIBITOR from Merck.

Restarted/ changed therapy (Tx): a person in the HIV/AIDS Drug Treatment program that was either CURRENTLY OFF THERAPY and now has been prescribed a new regimen or a person who has changed regimens.

Rifabutin (Mycobutin): an oral drug used to prevent mycobacterium avium complex (MAC) in people with advanced HIV infection. Rifabutin is also used in combination with other drugs for the treatment of active MAC infections.

Rilpivirine (Edurant, RPV): a NON-NUCELOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Janssen.

Ritonavir (Norvir, RTV): a PROTEASE INHIBITOR from Abbott. Ritonavir is commonly used to inhibit the liver enzyme metabolism of other protease inhibitors and improve their blood exposure (“booster”).

Saquinavir (Invirase, SQV): a PROTEASE INHIBITOR from Hoffman-La Roche.

Stavudine (Zerit, d4T): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Stopped all therapies (Tx): a person in the HIV/AIDS Drug Treatment program that stopped all therapies in this time period and is now CURRENTLY OFF THERAPY.

Stribild (STR): the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICISTAT, EMTRICITABINE and TENOFOVIR DF.

Tenofovir alafenamide (Tenofovir AF, TAF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV. It is currently available as a component of DESCOVY and GENVOYA.

Tenofovir disoproxil fumarate (Viread, Tenofovir DF, TDF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV and hepatitis B.

Tipranavir (Aptivus, TPV): a PROTEASE INHIBITOR from Boehringer Ingelheim that has activity against HIV in treatment-experienced patients.

Triple Therapy: the use of three drugs, most often a PROTEASE INHIBITOR or NON-NUCLEOSIDE ANALOG with two NUCLEOSIDE ANALOGS, in the treatment of HIV.

Triumeq (TRQ): the ViiV Healthcare’s trade name for a tablet containing DOLUTEGRAVIR, ABACAVIR and LAMIVUDINE.

Trizivir (TRZ): the ViiV Healthcare’s trade name for a tablet containing ABACAVIR, ZIDOVUDINE and LAMIVUDINE.

Truvada (TRU): the Gilead trade name for a tablet containing TENOFOVIR DF and EMTRICITABINE.





Monthly Report

Valganciclovir: an antiviral drug used to treat cytomegalovirus (CMV) retinitis.

Viral Load: the amount of HIV RNA per unit of blood plasma. An indicator of virus concentration and reproduction rate. HIV viral load is employed as a measure of the success of antiretroviral therapy.

Zidovudine (Retrovir, AZT): a NUCLEOSIDE ANALOG from ViiV Healthcare. AZT is also approved for preventing maternal-fetal HIV transmission.

